US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
US7393682B1
(en)
|
1993-03-19 |
2008-07-01 |
The Johns Hopkins University School Of Medicine |
Polynucleotides encoding promyostatin polypeptides
|
US6180134B1
(en)
*
|
1993-03-23 |
2001-01-30 |
Sequus Pharmaceuticals, Inc. |
Enhanced ciruclation effector composition and method
|
US5540935A
(en)
*
|
1993-12-06 |
1996-07-30 |
Nof Corporation |
Reactive vesicle and functional substance-fixed vesicle
|
US6132764A
(en)
|
1994-08-05 |
2000-10-17 |
Targesome, Inc. |
Targeted polymerized liposome diagnostic and treatment agents
|
US5512294A
(en)
*
|
1994-08-05 |
1996-04-30 |
Li; King C. |
Targeted polymerized liposome contrast agents
|
US5885613A
(en)
*
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
US5820873A
(en)
*
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US6673364B1
(en)
|
1995-06-07 |
2004-01-06 |
The University Of British Columbia |
Liposome having an exchangeable component
|
WO1997004787A1
(en)
*
|
1995-08-01 |
1997-02-13 |
Novartis Ag |
Liposomal oligonucleotide compositions
|
US5908624A
(en)
*
|
1996-06-27 |
1999-06-01 |
Albany Medical College |
Antigenic modulation of cells
|
US6245349B1
(en)
|
1996-02-23 |
2001-06-12 |
éLAN CORPORATION PLC |
Drug delivery compositions suitable for intravenous injection
|
US20050119470A1
(en)
*
|
1996-06-06 |
2005-06-02 |
Muthiah Manoharan |
Conjugated oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
*
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20050053976A1
(en)
*
|
1996-06-06 |
2005-03-10 |
Baker Brenda F. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20040147022A1
(en)
*
|
1996-06-06 |
2004-07-29 |
Baker Brenda F. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
US20040203024A1
(en)
*
|
1996-06-06 |
2004-10-14 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US20070275921A1
(en)
*
|
1996-06-06 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric Compounds That Facilitate Risc Loading
|
US8007784B1
(en)
|
1996-06-27 |
2011-08-30 |
Albany Medical College |
Antigenic modulation of cells
|
US6294614B1
(en)
|
1996-07-29 |
2001-09-25 |
K. K. Vayu |
Modified polymers containing poly(2-hydroxyethyl(meth)acrylate segment in the molecule
|
US6284267B1
(en)
|
1996-08-14 |
2001-09-04 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
US7368129B1
(en)
|
1996-08-14 |
2008-05-06 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
TW520297B
(en)
*
|
1996-10-11 |
2003-02-11 |
Sequus Pharm Inc |
Fusogenic liposome composition and method
|
US6056973A
(en)
*
|
1996-10-11 |
2000-05-02 |
Sequus Pharmaceuticals, Inc. |
Therapeutic liposome composition and method of preparation
|
ES2125817B1
(es)
*
|
1997-01-20 |
2000-01-01 |
Consejo Superior Investigacion |
Obtencion de nuevos cristales liquidos polimeros capaces de interaccionar con liposomas.
|
US5827533A
(en)
*
|
1997-02-06 |
1998-10-27 |
Duke University |
Liposomes containing active agents aggregated with lipid surfactants
|
DE19726186A1
(de)
*
|
1997-06-20 |
1998-12-24 |
Boehringer Ingelheim Int |
Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
US6197332B1
(en)
*
|
1997-08-13 |
2001-03-06 |
Chiron Corporation |
Lipid-conjugated polyamide compounds and related compositions and methods thereof
|
US6734171B1
(en)
|
1997-10-10 |
2004-05-11 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating nucleic acids in lipid bilayers
|
US6083923A
(en)
*
|
1997-10-31 |
2000-07-04 |
Isis Pharmaceuticals Inc. |
Liposomal oligonucleotide compositions for modulating RAS gene expression
|
US6986902B1
(en)
*
|
1998-04-28 |
2006-01-17 |
Inex Pharmaceuticals Corporation |
Polyanionic polymers which enhance fusogenicity
|
US20030215421A1
(en)
*
|
1999-07-21 |
2003-11-20 |
Mcdonald John R. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
US7157418B1
(en)
|
1998-07-22 |
2007-01-02 |
Osprey Pharmaceuticals, Ltd. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
US6355268B1
(en)
*
|
1998-09-16 |
2002-03-12 |
Alza Corporation |
Liposome-entrapped topoisomerase inhibitors
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6379698B1
(en)
|
1999-04-06 |
2002-04-30 |
Isis Pharmaceuticals, Inc. |
Fusogenic lipids and vesicles
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6251927B1
(en)
*
|
1999-04-20 |
2001-06-26 |
Medinox, Inc. |
Methods for treatment of sickle cell anemia
|
US7238368B2
(en)
*
|
1999-04-23 |
2007-07-03 |
Alza Corporation |
Releasable linkage and compositions containing same
|
US7303760B2
(en)
*
|
1999-04-23 |
2007-12-04 |
Alza Corporation |
Method for treating multi-drug resistant tumors
|
US7112337B2
(en)
|
1999-04-23 |
2006-09-26 |
Alza Corporation |
Liposome composition for delivery of nucleic acid
|
ATE340592T1
(de)
*
|
1999-04-23 |
2006-10-15 |
Alza Corp |
Konjugate enthaltend eine spaltbare bindung zur anwendung in einem liposom
|
DK1059092T3
(da)
*
|
1999-06-08 |
2006-03-27 |
Gentium Spa |
Anvendelse af komplekser af kationiske liposomer og polydeoxyribonukleotider som medikamenter
|
GB9918670D0
(en)
|
1999-08-06 |
1999-10-13 |
Celltech Therapeutics Ltd |
Biological product
|
US20020064520A1
(en)
*
|
1999-08-19 |
2002-05-30 |
Yanina Rozenberg |
Targeted artificial gene delivery
|
AU7868400A
(en)
|
1999-10-08 |
2001-04-23 |
Alza Corporation |
Neutral-cationic lipid for nucleic acid and drug delivery
|
US20040197390A1
(en)
*
|
2001-05-29 |
2004-10-07 |
Shi-Kun Huang |
Neutral-cationic lipid for systemic delivery of factor VIII gene
|
WO2001041738A2
(en)
*
|
1999-12-10 |
2001-06-14 |
Celator Technologies Inc. |
Lipid carrier compositions with protected surface reactive functions
|
CN101041079A
(zh)
*
|
1999-12-30 |
2007-09-26 |
诺瓦提斯公司 |
用于基因治疗的新的胶体合成载体
|
US20040009229A1
(en)
*
|
2000-01-05 |
2004-01-15 |
Unger Evan Charles |
Stabilized nanoparticle formulations of camptotheca derivatives
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US7230088B2
(en)
*
|
2001-07-03 |
2007-06-12 |
Mallinckrodt, Inc. |
Compounds for dual photodiagnosis and therapy
|
ES2236181T3
(es)
*
|
2000-01-28 |
2005-07-16 |
Alza Corporation |
Liposomas que contienen un compuesto atrapado en una solucion supersaturada.
|
US6928467B2
(en)
*
|
2000-02-02 |
2005-08-09 |
Inno Path Software, Inc. |
Apparatus and methods for providing data synchronization by facilitating data synchronization system design
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
CZ2003678A3
(cs)
*
|
2000-09-08 |
2004-03-17 |
Gryphon Therapeutics, Inc. |
Syntetické proteiny stimulující erytropoézu
|
US7118737B2
(en)
*
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
US6673334B1
(en)
*
|
2000-10-16 |
2004-01-06 |
Mallinkcrodt, Inc. |
Light sensitive compounds for instant determination of organ function
|
US6656451B1
(en)
*
|
2000-10-16 |
2003-12-02 |
Mallinckrodt, Inc. |
Indole compounds as novel dyes for organ function monitoring
|
US6669926B1
(en)
|
2000-10-16 |
2003-12-30 |
Mallinckrodt, Inc. |
Hydrophilic light absorbing indole compounds for determination of physiological function in critically ill patients
|
US7045283B2
(en)
|
2000-10-18 |
2006-05-16 |
The Regents Of The University Of California |
Methods of high-throughput screening for internalizing antibodies
|
WO2002046372A1
(en)
|
2000-12-08 |
2002-06-13 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
US6897196B1
(en)
*
|
2001-02-07 |
2005-05-24 |
The Regents Of The University Of California |
pH sensitive lipids based on ortho ester linkers, composition and method
|
US20020142304A1
(en)
*
|
2001-03-09 |
2002-10-03 |
Anderson Daniel G. |
Uses and methods of making microarrays of polymeric biomaterials
|
WO2002098952A1
(en)
*
|
2001-06-01 |
2002-12-12 |
Yamanouchi Europe B.V. |
Lipid-polymer-conjugates compositions
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA2633595A1
(en)
|
2001-06-20 |
2003-01-03 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
EP2221376B1
(de)
|
2001-06-21 |
2012-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
US20030054042A1
(en)
*
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
ATE486092T1
(de)
|
2001-09-18 |
2010-11-15 |
Genentech Inc |
Zusammensetzungen und verfahren für die diagnose von tumoren
|
NZ566396A
(en)
|
2001-10-09 |
2009-07-31 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
EP1575976A4
(de)
|
2001-11-02 |
2006-08-23 |
Insert Therapeutics Inc |
Verfahren und zusammensetzungen zur therapeutischen verwendung von rna-interferenz
|
JP2005508396A
(ja)
*
|
2001-11-02 |
2005-03-31 |
イントラディグム、コーポレイション |
核酸送達ビヒクルのための治療方法
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
EP2067472A1
(de)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
US20050260259A1
(en)
*
|
2004-04-23 |
2005-11-24 |
Bolotin Elijah M |
Compositions for treatment with glucagon-like peptide, and methods of making and using the same
|
US20030170299A1
(en)
*
|
2002-02-27 |
2003-09-11 |
Lee Robert J. |
Therapeutic methods for acute myeloid leukemia
|
DE60335608D1
(de)
*
|
2002-02-27 |
2011-02-17 |
Pharmain Corp |
Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
|
US7635463B2
(en)
|
2002-02-27 |
2009-12-22 |
Pharmain Corporation |
Compositions for delivery of therapeutics and other materials
|
AU2003220277A1
(en)
*
|
2002-03-12 |
2003-09-29 |
The Johns Hopkins University School Of Medicine |
Manganese ion regulation of reverse transcriptase activity and methods of modulating same
|
US20080220075A1
(en)
*
|
2002-03-20 |
2008-09-11 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
EP1490030B2
(de)
*
|
2002-03-20 |
2010-07-14 |
Elan Pharma International Limited |
Nanopartikelzusammensetzungen von angiogeneseinhibitoren
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
AU2003220917A1
(en)
*
|
2002-03-29 |
2003-10-13 |
Daiichi Pharmaceutical Co., Ltd. |
Phospholipid derivative
|
CA2481507A1
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
CA2490959C
(en)
|
2002-07-02 |
2013-04-16 |
Board Of Regents, The University Of Texas System |
Radiolabeled compounds and liposomes and their methods of making and using the same
|
EP2330194A3
(de)
|
2002-09-13 |
2011-10-12 |
Replicor, Inc. |
Nicht-sequenzkomplementäre antivirale Oligonukleotide
|
EP1549767A4
(de)
|
2002-09-26 |
2006-06-07 |
Amgen Inc |
Modulation der expression von forkhead-box o1a
|
US20040062748A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US7531604B2
(en)
*
|
2002-09-30 |
2009-05-12 |
Nof Corporation |
Phospholipid derivative
|
US7879351B2
(en)
*
|
2002-10-29 |
2011-02-01 |
Transave, Inc. |
High delivery rates for lipid based drug formulations, and methods of treatment thereof
|
JP5118302B2
(ja)
*
|
2002-10-29 |
2013-01-16 |
トランセイブ, インク. |
抗感染剤の徐放
|
AU2003304203A1
(en)
*
|
2002-10-29 |
2005-01-04 |
Pharmacia Corporation |
Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
|
US7718189B2
(en)
|
2002-10-29 |
2010-05-18 |
Transave, Inc. |
Sustained release of antiinfectives
|
AU2003290596B2
(en)
*
|
2002-11-05 |
2011-05-12 |
Isis Pharmaceuticals, Inc. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
WO2004044138A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
ES2417879T3
(es)
|
2002-11-13 |
2013-08-09 |
Genzyme Corporation |
Modulación antisentido de la expresión de la apolipoproteína B
|
JP4986109B2
(ja)
|
2002-11-13 |
2012-07-25 |
ジェンザイム・コーポレーション |
アポリポタンパク質b発現のアンチセンス調節
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
CA2510780A1
(en)
*
|
2002-12-19 |
2004-07-08 |
Alza Corporation |
Method of treating angiogenic tissue growth
|
BR0317752A
(pt)
*
|
2002-12-26 |
2005-11-22 |
Mountain View Pharmaceuticals |
Conjugados poliméricos de citocinas, quimiocinas, fatores do crescimento, hormÈnios polipeptìdicos e seus antagonistas com atividade de ligação a receptores conservada
|
TWI406672B
(zh)
*
|
2002-12-26 |
2013-09-01 |
Mountain View Pharmaceuticals |
生物效力增進的β干擾素聚合物共軛體
|
EP1591447B1
(de)
*
|
2003-01-06 |
2014-11-26 |
Nof Corporation |
Phospholipidderivate und deren herstellungsverfahren
|
WO2004063342A2
(en)
*
|
2003-01-09 |
2004-07-29 |
Invitrogen Corporation |
Cellular delivery and activation polypeptide-nucleic acid complexes
|
WO2004072284A1
(en)
|
2003-02-11 |
2004-08-26 |
Antisense Therapeutics Ltd |
Modulation of insulin like growth factor i receptor expression
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
PT2177620E
(pt)
*
|
2003-03-05 |
2015-02-16 |
Halozyme Inc |
Glicoproteína hialuronidase solúvel (shasegp), processo para preparação da mesma, suas utilizações e composições farmacêuticas que a compreendem
|
US20090123367A1
(en)
*
|
2003-03-05 |
2009-05-14 |
Delfmems |
Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
US20060104968A1
(en)
*
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
US7968115B2
(en)
|
2004-03-05 |
2011-06-28 |
Board Of Regents, The University Of Texas System |
Liposomal curcumin for treatment of cancer
|
WO2004083219A1
(ja)
*
|
2003-03-20 |
2004-09-30 |
Nof Corporation |
リン脂質誘導体
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
EP1610763A2
(de)
*
|
2003-03-31 |
2006-01-04 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Stabile liposome oder micellen mit einem sphingolipid und einem peg-lipopolymer
|
WO2004089339A2
(en)
|
2003-03-31 |
2004-10-21 |
Alza Corporation |
Lipid particles having asymmetric lipid coating and method of preparing same
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
AU2004231740A1
(en)
*
|
2003-04-17 |
2004-11-04 |
The Trustees Of Columbia University In The City Ofnew York |
Desmoglein 4 is a novel gene involved in hair growth
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
WO2005002507A2
(en)
|
2003-06-03 |
2005-01-13 |
Isis Pharmaceuticals, Inc. |
Modulation of survivin expression
|
US20040247624A1
(en)
*
|
2003-06-05 |
2004-12-09 |
Unger Evan Charles |
Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
|
EP1636342A4
(de)
*
|
2003-06-20 |
2008-10-08 |
Isis Pharmaceuticals Inc |
Oligomere verbindungen zur verwendung bei der modulation von genen
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
EP1663171B9
(de)
*
|
2003-08-26 |
2009-08-19 |
SmithKline Beecham Corporation |
heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen
|
US20070123480A1
(en)
*
|
2003-09-11 |
2007-05-31 |
Replicor Inc. |
Oligonucleotides targeting prion diseases
|
BRPI0413930A
(pt)
|
2003-09-18 |
2006-10-24 |
Isis Pharmaceuticals Inc |
composto oligomérico ou sal farmaceuticamente aceitável deste, composição farmacêutica ou veterinária, métodos para inibir a expressão de eif4e em uma célula, tecido ou órgão, para diminuir a proliferação de uma célula em que eif4e é expressado, e para prevenir ou tratar uma condição ou doença métodos para prevenir ou diminuir a angiogênese, e o crescimento de tumor em um paciente, oligonucleotìdeo de anti-sentido, composição farmacêutica ou veterinária, e, uso de um composto oligomérico ou sal farmaceuticamente aceitável deste
|
JP2007507430A
(ja)
|
2003-10-10 |
2007-03-29 |
メディテック リサーチ リミテッド |
疾患の治療におけるヒアルロナン合成および分解の調節法
|
WO2005041870A2
(en)
|
2003-10-24 |
2005-05-12 |
Ader Enterprises, Inc. |
Composition and method for the treatment of eye disease
|
US20050175683A1
(en)
*
|
2003-10-24 |
2005-08-11 |
Yuanpeng Zhang |
Preparation of lipid particles
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
US7915227B2
(en)
*
|
2003-11-14 |
2011-03-29 |
Het Nederlands Kanker Instituut |
Pharmaceutical formulations employing short-chain sphingolipids and their use
|
CA2546285C
(en)
|
2003-11-17 |
2015-12-29 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
KR20060130057A
(ko)
|
2003-11-21 |
2006-12-18 |
알자 코포레이션 |
절단가능한 peg 표면 변형을 갖는 리포좀-dna복합체에 의해 매개되는 유전자 송달
|
WO2005070466A2
(en)
*
|
2004-01-15 |
2005-08-04 |
Alza Corporation |
Liposome composition for delivery of therapeutic agents
|
JP2007520222A
(ja)
|
2004-01-20 |
2007-07-26 |
アイシス ファーマシューティカルズ インコーポレイテッド |
グルココルチコイドレセプター発現の調節
|
US7468431B2
(en)
*
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US8784881B2
(en)
|
2004-03-05 |
2014-07-22 |
Board Of Regents, The University Of Texas System |
Liposomal curcumin for treatment of diseases
|
US8569474B2
(en)
*
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP2365077B1
(de)
|
2004-03-12 |
2013-05-08 |
Alnylam Pharmaceuticals, Inc. |
iRNA-Agenten zum VEGF-Targeting
|
US8790919B2
(en)
|
2004-03-15 |
2014-07-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNase H
|
US7187286B2
(en)
|
2004-03-19 |
2007-03-06 |
Applera Corporation |
Methods and systems for using RFID in biological field
|
WO2005097207A2
(en)
*
|
2004-03-26 |
2005-10-20 |
Curis, Inc. |
Rna interference modulators of hedgehog signaling and uses thereof
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
CN1997399A
(zh)
*
|
2004-04-21 |
2007-07-11 |
阿尔扎公司 |
可在温和硫解条件下释放的聚合物共轭物
|
US20060019972A1
(en)
*
|
2004-04-27 |
2006-01-26 |
California Institute Of Technology |
Methods of treating cancer by inhibiting histone gene expression
|
DK1746976T3
(en)
|
2004-05-03 |
2017-04-10 |
Merrimack Pharmaceuticals Inc |
LIPOSOMES SUITABLE FOR PHARMACEUTICAL SUPPLY
|
US20090048192A1
(en)
*
|
2004-06-03 |
2009-02-19 |
Isis Pharmaceuticals, Inc. |
Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
|
US8394947B2
(en)
*
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
EP1766052A4
(de)
*
|
2004-06-03 |
2009-12-16 |
Isis Pharmaceuticals Inc |
Chimärische oligomere zusammensetzungen mit gap
|
CA2568735A1
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
JP2008502788A
(ja)
*
|
2004-06-08 |
2008-01-31 |
アルザ コーポレイション |
4成分縮合反応による高分子コンジュゲートの調製
|
US7884086B2
(en)
*
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US8932627B2
(en)
*
|
2004-09-09 |
2015-01-13 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Liposomal compositions of glucocorticoid and glucocorticoid derivatives
|
EP1793805A1
(de)
*
|
2004-09-09 |
2007-06-13 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Liposomale formulierungen mit einem amphipatischen schwachbasen-artigen tempamin zur behandlung von neurodegenerativen erkrankungen
|
US7635754B2
(en)
*
|
2004-09-22 |
2009-12-22 |
Aerovance, Inc. |
Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
|
CA2581896C
(en)
|
2004-09-29 |
2015-11-10 |
Mount Sinai School Of Medicine Of New York University |
Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis
|
WO2006042112A2
(en)
|
2004-10-05 |
2006-04-20 |
California Institute Of Technology |
Aptamer regulated nucleic acids and uses thereof
|
AU2005295072A1
(en)
*
|
2004-10-08 |
2006-04-20 |
Alza Corporation |
Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
|
TW200612993A
(en)
*
|
2004-10-08 |
2006-05-01 |
Alza Corp |
Lipopolymer conjugates
|
EP1809254A2
(de)
*
|
2004-10-28 |
2007-07-25 |
Alza Corporation |
Gefriergetrocknete liposomformulierungen und verfahren
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
US20090285878A1
(en)
|
2004-11-05 |
2009-11-19 |
Tekmira Pharmaceuticals Corporation |
Compositions and methods for stabilizing liposomal drug formulations
|
EP1817004A2
(de)
*
|
2004-11-15 |
2007-08-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Kombinationstherapie, vorzugsweise aus einem ceramid mit einem zytotoxischen mittel
|
US20090104254A1
(en)
|
2004-12-22 |
2009-04-23 |
Rutgers, The State University Of New Jersey |
Controlled Release Hydrogels
|
US8664392B2
(en)
|
2004-12-23 |
2014-03-04 |
Medibeacon, LLC |
Pyrazine derivatives for bioconjugation
|
AU2006213686A1
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
AU2006223498A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
US7427605B2
(en)
|
2005-03-31 |
2008-09-23 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
EP1885404A2
(de)
*
|
2005-06-01 |
2008-02-13 |
Alza Corporation |
Biokonjugationsreaktionen für acylierende polyethylenglykol reagentien
|
US20070015701A1
(en)
*
|
2005-06-01 |
2007-01-18 |
Samuel Zalipsky |
Macromolecular conjugates of bone morphogenetic protein-7
|
JP5777846B2
(ja)
|
2005-06-15 |
2015-09-09 |
マサチューセッツ インスティテュート オブ テクノロジー |
アミン含有脂質およびその使用
|
WO2007005754A2
(en)
*
|
2005-07-01 |
2007-01-11 |
Alza Corporation |
Liposomal delivery vehicle for hydrophobic drugs
|
US8591457B2
(en)
|
2005-08-10 |
2013-11-26 |
Alza Corporation |
Method for making a needle-free jet injection drug delivery device
|
EP1926489A2
(de)
*
|
2005-09-12 |
2008-06-04 |
Alza Corporation |
Liposome zur behandlung von mehrfach-myelomen
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
JP2009513716A
(ja)
|
2005-11-01 |
2009-04-02 |
アルナイラム ファーマシューティカルズ インコーポレイテッド |
RNAiによるインフルエンザウイルス複製の抑制
|
DE102005053066A1
(de)
|
2005-11-04 |
2007-05-10 |
Basf Ag |
Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
|
CA2630602A1
(en)
|
2005-11-21 |
2007-05-31 |
Isis Pharmaceuticals, Inc. |
Modulation of eif4e-bp2 expression
|
CN101365424A
(zh)
*
|
2005-12-08 |
2009-02-11 |
耶路撒冷希伯来大学伊森姆研究发展公司 |
通过超声辐射改变脂质体组成的方法
|
US8226975B2
(en)
|
2005-12-08 |
2012-07-24 |
Insmed Incorporated |
Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
|
CN101325976A
(zh)
*
|
2005-12-09 |
2008-12-17 |
巴斯夫欧洲公司 |
聚乙烯基内酰胺-聚氧化烯嵌段共聚物作为微水溶性化合物的加溶剂的用途
|
KR101872061B1
(ko)
|
2005-12-19 |
2018-06-27 |
파마인 코포레이션 |
치료제를 전달하기 위한 소수성 코어 담체 조성물, 이 조성물의 제조 방법 및 그 조성물의 이용 방법
|
WO2007089611A2
(en)
|
2006-01-26 |
2007-08-09 |
Isis Pharmaceuticals Inc. |
Compositions and their uses directed to huntingtin
|
CA2644520A1
(en)
*
|
2006-03-02 |
2007-09-13 |
Mallinckrodt Inc. |
Thiadiazole compounds and their use in phototherapy
|
JP2009529533A
(ja)
*
|
2006-03-10 |
2009-08-20 |
マリンクロット インコーポレイテッド |
光活性の化合物および組成物、ならびにそれらの使用方法
|
CN101448849B
(zh)
|
2006-03-31 |
2013-08-21 |
阿尔尼拉姆医药品有限公司 |
抑制Eg5基因表达的组合物和方法
|
US20090306349A1
(en)
*
|
2006-03-31 |
2009-12-10 |
Rampak Corp |
Binding partners with immunoglobulin domains modified to have extended half-life
|
AU2007243946B2
(en)
|
2006-04-05 |
2012-11-29 |
Curis, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
WO2007127919A2
(en)
|
2006-04-28 |
2007-11-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the jc virus
|
AU2007245599B2
(en)
*
|
2006-05-03 |
2012-05-10 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
WO2007133627A2
(en)
*
|
2006-05-10 |
2007-11-22 |
Alza Corporation |
Method for making liposomes conjugated with temperature-sensitive ligands
|
BRPI0712034A2
(pt)
|
2006-05-19 |
2012-01-10 |
Alnylam Pharmaceuticals Inc |
modulação de rnai de aha e usos terapêuticos do mesmo
|
WO2007137220A2
(en)
|
2006-05-22 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
US20090209625A1
(en)
*
|
2006-05-23 |
2009-08-20 |
Sanjay Bhanot |
Modulation of chrebp expression
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
EP2050828A3
(de)
|
2006-06-12 |
2009-08-26 |
Oncomethylome Sciences S.A. |
Methylierungsmarker zur frühen Erkennung und Prognose von Dickdarmkrebs
|
EP2029554B1
(de)
|
2006-06-22 |
2014-03-19 |
MediBeacon, LLC |
Pyrazinderivate und ihre verwendung zur nierenüberwachung
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
CA2600220C
(en)
*
|
2006-09-07 |
2014-12-09 |
Canadian Blood Services |
Surface cross-linked lipidic particles, methods of production and uses therefor
|
WO2008058291A2
(en)
|
2006-11-09 |
2008-05-15 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
US8278415B2
(en)
|
2006-12-21 |
2012-10-02 |
Centocor, Inc. |
Dimeric high affinity EGFR constructs and uses thereof
|
US8834920B2
(en)
|
2006-12-21 |
2014-09-16 |
Alza Corporation |
Liposome composition for targeting egfr receptor
|
WO2008079973A2
(en)
*
|
2006-12-21 |
2008-07-03 |
Centocor, Inc. |
Egfr binding peptides and uses thereof
|
US8048998B2
(en)
*
|
2007-01-19 |
2011-11-01 |
Exiqon A/S |
Mediated cellular delivery of LNA oligonucleotides
|
EP2114981B1
(de)
|
2007-01-29 |
2013-05-08 |
Isis Pharmaceuticals, Inc. |
Verbindungen und Methoden zur Modulation der Proteinexpression
|
AU2008218199B2
(en)
|
2007-02-22 |
2013-10-31 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
AP2014007971A0
(en)
|
2007-03-29 |
2014-09-30 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expressionof a gene from the ebola
|
WO2008137717A1
(en)
|
2007-05-04 |
2008-11-13 |
Transave, Inc. |
Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
|
US9114081B2
(en)
|
2007-05-07 |
2015-08-25 |
Insmed Incorporated |
Methods of treating pulmonary disorders with liposomal amikacin formulations
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
US9333214B2
(en)
|
2007-05-07 |
2016-05-10 |
Insmed Incorporated |
Method for treating pulmonary disorders with liposomal amikacin formulations
|
WO2008141278A1
(en)
*
|
2007-05-11 |
2008-11-20 |
Centocor, Inc. |
Method for preparing antibody conjugates
|
AR066984A1
(es)
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
|
WO2009011855A2
(en)
*
|
2007-07-16 |
2009-01-22 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
EP2173781A1
(de)
*
|
2007-07-26 |
2010-04-14 |
Basf Se |
Verfahren zur herstellung von durch pfropfpolymerisation in lösung erhaltenen copolymeren auf basis von polyethern in fester form
|
US7960336B2
(en)
|
2007-08-03 |
2011-06-14 |
Pharmain Corporation |
Composition for long-acting peptide analogs
|
EP2184355A4
(de)
*
|
2007-08-09 |
2011-04-27 |
Daiichi Sankyo Co Ltd |
Mit einem hydrophoben molekül modifizierter antikörper
|
US8563527B2
(en)
*
|
2007-08-20 |
2013-10-22 |
Pharmain Corporation |
Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
US8865667B2
(en)
*
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
CN101878229A
(zh)
*
|
2007-09-28 |
2010-11-03 |
巴塞尔大学医院 |
用于治疗癌症的免疫脂质体
|
JP2010539978A
(ja)
|
2007-10-02 |
2010-12-24 |
アムジェン インコーポレイテッド |
マイクロ−rnaおよびその前駆体にハイブリダイズしうる核酸を用いるエリスロポエチンの増加
|
CA2704560A1
(en)
*
|
2007-11-05 |
2009-05-14 |
Baltic Technology Development, Ltd. |
Use of oligonucleotides with modified bases in hybridization of nucleic acids
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
US7871985B2
(en)
|
2007-12-10 |
2011-01-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor VII gene
|
US20090176892A1
(en)
|
2008-01-09 |
2009-07-09 |
Pharmain Corporation |
Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
|
CA2716793A1
(en)
|
2008-03-05 |
2009-09-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 and vegf genes
|
EP2105145A1
(de)
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
|
AU2009232355A1
(en)
|
2008-04-04 |
2009-10-08 |
Calando Pharmaceuticals, Inc. |
Compositions and use of EPAS1 inhibitors
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
US20100003315A1
(en)
|
2008-07-02 |
2010-01-07 |
Willeford Kenneth L |
Method and Composition for the Treatment of Skin Conditions
|
JP5642673B2
(ja)
*
|
2008-07-10 |
2014-12-17 |
セリナ・セラピユーテイツクス・インコーポレーテツド |
不活性末端基を有するポリオキサゾリン類、保護された開始基から調製されるポリオキサゾリン類及び関連化合物
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
EP2323667A4
(de)
*
|
2008-08-07 |
2012-07-25 |
Isis Pharmaceuticals Inc |
Modulierung der transthyretin-expression durch behandlung von zns-erkrankungen
|
JP5420668B2
(ja)
|
2008-08-25 |
2014-02-19 |
エクスカリアード・ファーマシューティカルズ,インコーポレイテッド |
結合組織成長因子を対象とするアンチセンスオリゴヌクレオチドおよびその使用
|
US8318693B2
(en)
|
2008-09-02 |
2012-11-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mutant EGFR gene
|
AU2009293658A1
(en)
|
2008-09-22 |
2010-03-25 |
James Cardia |
Reduced size self-delivering RNAi compounds
|
CA2739170A1
(en)
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
US9173840B2
(en)
|
2008-10-09 |
2015-11-03 |
Northeastern University |
Multifunctional self-assembling polymeric nanosystems
|
US8168775B2
(en)
|
2008-10-20 |
2012-05-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
MX2011004859A
(es)
|
2008-11-07 |
2011-08-03 |
Massachusetts Inst Technology |
Lipidoides de aminoalcohol y usos de los mismos.
|
JP6099868B2
(ja)
|
2008-12-04 |
2017-03-22 |
クルナ・インコーポレーテッド |
サーチュイン1(sirt1)に対する天然アンチセンス転写物の抑制によるサーチュイン1関連疾患の治療
|
EP2370582B1
(de)
|
2008-12-04 |
2017-05-10 |
CuRNA, Inc. |
Behandlung von tumorsuppressorgen-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen das gen
|
WO2010065792A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
CA2746514C
(en)
|
2008-12-10 |
2018-11-27 |
Alnylam Pharmaceuticals, Inc. |
Gnaq targeted dsrna compositions and methods for inhibiting expression
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
CN102439149B
(zh)
|
2009-02-12 |
2018-01-02 |
库尔纳公司 |
通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
|
ES2762610T3
(es)
|
2009-02-12 |
2020-05-25 |
Curna Inc |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
JP6250263B2
(ja)
|
2009-03-04 |
2017-12-20 |
クルナ・インコーポレーテッド |
サーチュイン1(sirt1)に対する天然アンチセンス転写物の抑制によるsirt1関連疾患の治療
|
EP2228059A1
(de)
|
2009-03-12 |
2010-09-15 |
Universitätsspital Basel |
Chemotherapeutische Zusammensetzung für die Krebsbehandlung
|
CN104922699B
(zh)
|
2009-03-12 |
2020-07-24 |
阿尔尼拉姆医药品有限公司 |
脂质配制的组合物以及用于抑制Eg5和VEGF基因表达的方法
|
US9464287B2
(en)
|
2009-03-16 |
2016-10-11 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
|
CN102549159B
(zh)
|
2009-03-17 |
2016-08-10 |
库尔纳公司 |
通过抑制针对δ样1同源物(DLK1)的天然反义转录物来治疗DLK1相关的疾病
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
EP3248618A1
(de)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
|
US8318690B2
(en)
|
2009-05-01 |
2012-11-27 |
Curna, Inc. |
Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG
|
CN103223177B
(zh)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
CN102803492B
(zh)
|
2009-05-06 |
2016-06-29 |
库尔纳公司 |
通过抑制针对三重四脯氨酸(ttp)的天然反义转录物来治疗ttp相关疾病
|
EP2432881B1
(de)
|
2009-05-18 |
2017-11-15 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem reprogrammierungsfaktor durch hemmung des natürlichen antisense-transkripts zu einem reprogrammierungsfaktor
|
CA2762987A1
(en)
|
2009-05-22 |
2010-11-25 |
Joseph Collard |
Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
|
JP5960049B2
(ja)
|
2009-05-28 |
2016-08-02 |
クルナ・インコーポレーテッド |
抗ウイルス遺伝子に対する天然アンチセンス転写物の抑制による抗ウイルス遺伝子関連疾患の治療
|
WO2010143193A1
(en)
|
2009-06-11 |
2010-12-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Targeted liposomes comprising n-containing bisphosphonates and uses thereof
|
JP6128846B2
(ja)
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
パラオキソナーゼ(pon1)に対する天然アンチセンス転写物の抑制によるpon1遺伝子関連疾患の治療
|
US20120171170A1
(en)
|
2009-06-16 |
2012-07-05 |
Opko Curna, Llc |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
EP2446036B1
(de)
|
2009-06-24 |
2017-03-01 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit tumornekrose faktor-rezeptor 2 (tnfr2) mittels hemmung des natürlichen antisense-transkripts gegen tnfr2
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
CN102762731B
(zh)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
|
EP2464336A4
(de)
|
2009-08-14 |
2013-11-20 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der expression eines gens aus dem ebolavirus
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP3252068A3
(de)
|
2009-10-12 |
2018-03-14 |
Larry J. Smith |
Verfahren und zusammensetzungen zur modulation der genexpression unter verwendung in-vivo- oder in-vitro-verabreichten arzneistoffen auf oligonukleotidbasis
|
CA2778442A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
US20120244169A1
(en)
|
2009-11-06 |
2012-09-27 |
Fibrogen, Inc. |
Treatment for Radiation-Induced Disorders
|
AU2010324686B2
(en)
|
2009-11-30 |
2016-05-19 |
Genentech, Inc. |
Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
|
ME03327B
(de)
|
2009-12-01 |
2019-10-20 |
Translate Bio Inc |
Steroidderivat zur ausgabe von mrna bei humangenetischen erkrankungen
|
US8901129B2
(en)
|
2009-12-11 |
2014-12-02 |
Genecode As |
Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
|
RU2639550C2
(ru)
|
2009-12-16 |
2017-12-21 |
Курна, Инк. |
Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1
|
KR101891352B1
(ko)
|
2009-12-23 |
2018-08-24 |
큐알엔에이, 인크. |
간세포 성장 인자(hgf)에 대한 천연 안티센스 전사체의 억제에 의한 hgf 관련 질환의 치료
|
CN102781480B
(zh)
|
2009-12-23 |
2018-07-27 |
库尔纳公司 |
通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
|
CA2785173A1
(en)
|
2009-12-29 |
2011-07-28 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
WO2011090741A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
US8946181B2
(en)
|
2010-01-04 |
2015-02-03 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
|
EP2521785B1
(de)
|
2010-01-06 |
2022-03-09 |
CuRNA, Inc. |
Inhibition des natürlichen antisense-transkripts des pankreasentwicklungsgens zur verwendung in der behandlung von pankreatischen entwicklungsgenbezogenen krankheiten
|
US9200277B2
(en)
|
2010-01-11 |
2015-12-01 |
Curna, Inc. |
Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
|
EP2525808A2
(de)
|
2010-01-19 |
2012-11-28 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin als behandlungsmittel für männliche fortpflanzungsstörungen
|
CA2786568A1
(en)
|
2010-01-25 |
2011-07-28 |
Curna, Inc. |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
US20130052259A1
(en)
|
2010-02-01 |
2013-02-28 |
Yechezkel Barenholz |
Liposomes comprising amphipathic drugs and method for their preparation
|
JP5976548B2
(ja)
|
2010-02-22 |
2016-08-23 |
カッパーアールエヌエー,インコーポレイテッド |
Pycr1に対する天然アンチセンス転写物の阻害によるピロリン−5−カルボン酸レダクターゼ1(pycr1)関連疾患の治療
|
AU2011221226A1
(en)
|
2010-02-23 |
2012-08-16 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA2792291A1
(en)
|
2010-03-29 |
2011-10-06 |
Kumamoto University |
Sirna therapy for transthyretin (ttr) related ocular amyloidosis
|
CA2795281A1
(en)
|
2010-04-09 |
2011-10-13 |
Curna, Inc. |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
KR20180026798A
(ko)
|
2010-04-29 |
2018-03-13 |
아이오니스 파마수티컬즈, 인코포레이티드 |
트랜스티레틴 발현의 조절
|
RU2693462C2
(ru)
|
2010-05-03 |
2019-07-03 |
Курна, Инк. |
Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
|
JP2013533732A
(ja)
|
2010-05-03 |
2013-08-29 |
ジェネンテック, インコーポレイテッド |
腫瘍の診断と治療のための組成物と方法
|
CN109593814A
(zh)
|
2010-05-12 |
2019-04-09 |
哥伦比亚大学纽约管理委员会 |
筛选分析、鉴别药剂的方法及药物组合物
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
RU2585229C2
(ru)
|
2010-05-26 |
2016-05-27 |
Курна, Инк. |
Лечение заболеваний, связанных с атональным гомологом 1 (атон1), путем ингибирования природного антисмыслового транскрипта гена атон1
|
CA2801066C
(en)
|
2010-06-02 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
CN103080125A
(zh)
|
2010-07-02 |
2013-05-01 |
安吉奥开米公司 |
用于治疗性结合物的短且含d氨基酸的多肽及其使用
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー,インコーポレイテッド |
Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療
|
EP2609135A4
(de)
|
2010-08-26 |
2015-05-20 |
Massachusetts Inst Technology |
Poly(beta-amino-alkohole), ihre herstellung und verwendungen davon
|
EP2625197B1
(de)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Smoothened-mutant und verfahren zu seiner anwendung
|
EP2625274B1
(de)
|
2010-10-06 |
2017-07-19 |
CuRNA, Inc. |
Behandlung sialidase-4-(neu4)-vermittelter erkrankungen durch hemmung des natürlichen antisense-transkripts gegen neu4
|
US20140086975A1
(en)
|
2010-10-15 |
2014-03-27 |
Rutgers, The State University Of New Jersey |
Hydrogel formulation for dermal and ocular delivery
|
US9222088B2
(en)
|
2010-10-22 |
2015-12-29 |
Curna, Inc. |
Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
|
DK2633052T3
(en)
|
2010-10-27 |
2018-07-16 |
Curna Inc |
TREATMENT OF INTERFERON-RELATED DEVELOPMENT REGULATOR 1 (IFRD1) -RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPT TO IFRD1
|
US20140134181A1
(en)
|
2010-11-05 |
2014-05-15 |
Kenneth E. Lipson |
Treatment Method For Lung Remodeling Diseases
|
WO2012064824A1
(en)
|
2010-11-09 |
2012-05-18 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
WO2012065044A2
(en)
|
2010-11-12 |
2012-05-18 |
Purdue Research Foundation |
Treating bladder tumor cells using fibronectin attachment protein as a target
|
RU2608493C2
(ru)
|
2010-11-23 |
2017-01-18 |
Курна, Инк. |
Лечение заболеваний, связанных с nanog, путем ингибирования природного антисмыслового транскрипта nanog
|
US9127275B2
(en)
|
2010-12-10 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
US9193973B2
(en)
|
2010-12-10 |
2015-11-24 |
Alynylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (EPO) production
|
AU2011353698B2
(en)
|
2011-01-05 |
2017-05-11 |
Livon Laboratories |
Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
|
EP2670393B8
(de)
|
2011-01-31 |
2016-10-05 |
Nanobiotix |
Verfahren zur überwachung der freisetzung von liposomen aus einem produkt von interesse mithilfe superparamagnetischer nanopartikel
|
CN103635197A
(zh)
|
2011-02-02 |
2014-03-12 |
埃克斯利尔德生物制药公司 |
使用靶向结缔组织生长因子(ctgf)的反义化合物治疗疤痕疙瘩或肥大性疤痕的方法
|
EP2907504B1
(de)
|
2011-02-08 |
2017-06-28 |
Halozyme, Inc. |
Zusammensetzung und Lipidformulierung eines Hyaluronan-abbauenden Enzyms und seiner Verwendung zur Behandlung von benigner Prostatahyperplasie
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
MX345504B
(es)
*
|
2011-03-02 |
2017-02-02 |
Sensulin Llc |
Composiciones de vesicula.
|
DK2691443T3
(da)
|
2011-03-28 |
2021-05-03 |
Massachusetts Inst Technology |
Konjugerede lipomerer og anvendelser af disse
|
MX360349B
(es)
|
2011-03-29 |
2018-10-30 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
|
EP2508176A1
(de)
|
2011-04-08 |
2012-10-10 |
Lipotarg Gmbh |
Neues Kombinatonsbehandlung für Krebs
|
KR101839177B1
(ko)
|
2011-04-13 |
2018-03-15 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Ptpib 발현의 안티센스 조절
|
EP2706988B1
(de)
*
|
2011-05-12 |
2019-12-04 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Liposome mit polymerkonjugierten lipiden und verwendungen davon
|
SG195252A1
(en)
|
2011-06-02 |
2013-12-30 |
Harvard College |
Methods and uses for ex vivo tissue culture systems
|
BR112013031553A2
(pt)
|
2011-06-08 |
2020-11-10 |
Shire Human Genetic Therapies, Inc. |
composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
|
TWI678375B
(zh)
|
2011-06-09 |
2019-12-01 |
可娜公司 |
藉由抑制共濟蛋白(frataxin,fxn)之天然反股轉錄本治療fxn相關疾病
|
AU2012271357A1
(en)
|
2011-06-16 |
2013-05-02 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
US9068184B2
(en)
|
2011-06-21 |
2015-06-30 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein C (PROC) genes
|
AU2012272860A1
(en)
|
2011-06-21 |
2013-12-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
|
CA2839896A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
EP3597750B1
(de)
|
2011-06-23 |
2022-05-04 |
Alnylam Pharmaceuticals, Inc. |
Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
|
AU2012275841A1
(en)
|
2011-06-27 |
2014-01-16 |
The Jackson Laboratory |
Methods and compositions for treatment of cancer and autoimmune disease
|
SI2731591T1
(sl)
|
2011-07-13 |
2021-02-26 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Liposomi ko-inkapsulirajoči bifosfonat in amfipatično sredstvo
|
WO2013019857A2
(en)
|
2011-08-01 |
2013-02-07 |
Alnylam Pharmaceuticals, Inc. |
Method for improving the success rate of hematopoietic stem cell transplants
|
JP6092226B2
(ja)
|
2011-09-20 |
2017-03-08 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
Gcgr発現のアンチセンス調整
|
EP2758074B1
(de)
|
2011-09-23 |
2020-04-22 |
Loma Linda University |
Bakterienstämme zur expression von methylasegenen und verwendungen davon
|
CN103796668B
(zh)
*
|
2011-09-28 |
2016-12-28 |
泰尔茂株式会社 |
含有血红蛋白的脂质体及其制造方法
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
AU2012328680A1
(en)
|
2011-10-25 |
2014-05-01 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of GCCR expression
|
WO2013087920A1
(en)
|
2011-12-16 |
2013-06-20 |
Nanobiotix |
Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof
|
US20150004219A1
(en)
|
2012-02-02 |
2015-01-01 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Stable liposomes for drug delivery
|
HUE040179T2
(hu)
|
2012-03-15 |
2019-02-28 |
Curna Inc |
Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
LT2852391T
(lt)
|
2012-05-21 |
2022-03-10 |
Insmed Incorporated |
Plaučių infekcijų gydymo būdai
|
EP3536787A1
(de)
|
2012-06-08 |
2019-09-11 |
Translate Bio, Inc. |
Nukleaseresistente polynukleotide und verwendungen davon
|
CA2884870C
(en)
|
2012-08-13 |
2022-03-29 |
Massachusetts Institute Of Technology |
Amine-containing lipidoids and uses thereof
|
EP2943194A1
(de)
|
2012-09-17 |
2015-11-18 |
Chemedest Ltd. |
Behandlung peripherer neuropathie mit gfr (alpha)-typ-3 -rezeptoragonisten
|
EP2925298B1
(de)
|
2012-11-29 |
2019-05-29 |
Insmed Incorporated |
Stabilisierte vancomycin-formulierungen
|
CA2894846A1
(en)
|
2012-12-12 |
2014-06-19 |
Temple University - Of The Commonwealth System Of Higher Education |
Compositions and methods for treatment of cancer
|
AU2014203873A1
(en)
|
2013-01-07 |
2015-07-30 |
Biomedical Research Models, Inc. |
Therapeutic vaccines for treating herpes simplex virus type 2 infections
|
KR20150128687A
(ko)
|
2013-03-14 |
2015-11-18 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna의 정제 방법
|
AU2014236305B2
(en)
|
2013-03-14 |
2019-01-17 |
Ethris Gmbh |
CFTR mRNA compositions and related methods and uses
|
WO2014145042A1
(en)
|
2013-03-15 |
2014-09-18 |
Loma Linda University |
Treatment of autoimmune diseases
|
US10052364B2
(en)
|
2013-03-15 |
2018-08-21 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
EP3708184A1
(de)
|
2013-03-27 |
2020-09-16 |
The General Hospital Corporation |
Verfahren und mittel zur behandlung von morbus alzheimer
|
US9315472B2
(en)
|
2013-05-01 |
2016-04-19 |
Massachusetts Institute Of Technology |
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
|
US10246708B2
(en)
|
2013-05-06 |
2019-04-02 |
Alnylam Pharmaceuticals, Inc. |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
DK3007704T3
(da)
|
2013-06-13 |
2021-03-29 |
Antisense Therapeutics Ltd |
Kombinationsterapi til akromegali
|
US9827552B2
(en)
|
2013-07-17 |
2017-11-28 |
Clemson University |
Functionalized lipid modification of solid phase surfaces for use in chromatography
|
KR102275504B1
(ko)
|
2013-09-05 |
2021-07-09 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
산성 알파-글루코시다제 내 안티센스-유도된 엑손2 포함
|
WO2015042466A2
(en)
|
2013-09-19 |
2015-03-26 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for inhibiting jc virus (jcv)
|
TW202003849A
(zh)
|
2013-10-02 |
2020-01-16 |
美商艾爾妮蘭製藥公司 |
抑制lect2基因表現之組合物及方法
|
NZ757749A
(en)
|
2013-10-04 |
2022-07-01 |
Icahn School Med Mount Sinai |
Compositions and methods for inhibiting expression of the alas1 gene
|
EA201690576A1
(ru)
|
2013-10-22 |
2016-10-31 |
Шир Хьюман Дженетик Терапис, Инк. |
Липидные композиции для доставки матричной рнк
|
WO2015061500A1
(en)
|
2013-10-22 |
2015-04-30 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for argininosuccinate synthetase deficiency
|
EA034103B1
(ru)
|
2013-10-22 |
2019-12-27 |
Транслейт Био, Инк. |
СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
US20170044232A1
(en)
|
2014-02-04 |
2017-02-16 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US11083730B2
(en)
|
2014-04-21 |
2021-08-10 |
Heron Therapeutics, Inc. |
Long-acting polymeric delivery systems
|
CN114886899B
(zh)
|
2014-04-21 |
2024-02-13 |
赫伦治疗有限公司 |
长效聚合物输送系统
|
CN117402871A
(zh)
|
2014-04-25 |
2024-01-16 |
川斯勒佰尔公司 |
信使rna的纯化方法
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
NZ726256A
(en)
|
2014-05-15 |
2022-11-25 |
Insmed Inc |
Methods for treating pulmonary non-tuberculous mycobacterial infections
|
JP6557722B2
(ja)
|
2014-05-30 |
2019-08-07 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
核酸の送達のための生分解性脂質
|
AU2015279968B2
(en)
|
2014-06-24 |
2019-11-14 |
Translate Bio, Inc. |
Stereochemically enriched compositions for delivery of nucleic acids
|
US10487314B2
(en)
|
2014-06-26 |
2019-11-26 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
|
EP3164379A1
(de)
|
2014-07-02 |
2017-05-10 |
Massachusetts Institute of Technology |
Lipidoide aus polyaminfettsäure und verwendungen davon
|
WO2016033555A1
(en)
|
2014-08-28 |
2016-03-03 |
Halozyme, Inc. |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
JP7175608B2
(ja)
|
2014-11-19 |
2022-11-21 |
ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク |
加齢に伴うフレイルのための治療としてのオステオカルシン
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
AU2015364508A1
(en)
|
2014-12-18 |
2017-07-06 |
Alnylam Pharmaceuticals, Inc. |
ReversirTM compounds
|
EP3247386A4
(de)
|
2015-01-20 |
2018-10-03 |
The Children's Medical Center Corporation |
Anti-net-verbindungen zur behandlung und prävention von fibrose und wundheilungsförderung
|
EP3270898B1
(de)
|
2015-03-17 |
2021-05-05 |
Lipomedix Pharmaceuticals Ltd. |
Verfahren zur behandlung von blasenkrebs
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
WO2016189125A1
(en)
|
2015-05-28 |
2016-12-01 |
Nanobiotix |
Nanoparticles for use as a therapeutic vaccine
|
WO2016196670A1
(en)
|
2015-06-01 |
2016-12-08 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon exclusion in type vii collagen
|
JP6768722B2
(ja)
|
2015-07-02 |
2020-10-14 |
大塚製薬株式会社 |
凍結乾燥医薬組成物
|
AU2016295168B2
(en)
|
2015-07-17 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
WO2017027622A1
(en)
|
2015-08-11 |
2017-02-16 |
Scintillon Institute For Biomedical And Bioenergy Research |
Optical analyses of particles and vesicles
|
WO2017048843A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the alas1 gene
|
US10954300B2
(en)
|
2015-09-28 |
2021-03-23 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
WO2017062835A2
(en)
|
2015-10-09 |
2017-04-13 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
CN108366965B
(zh)
|
2015-10-16 |
2021-10-01 |
易普森生物制药有限公司 |
稳定喜树碱药物组合物
|
CA3007424A1
(en)
|
2015-11-05 |
2017-05-11 |
Children's Hospital Los Angeles |
"mobilizing leukemia cells"
|
ES2956013T3
(es)
|
2015-11-10 |
2023-12-11 |
Childrens Res Institute Childrens National Medical Center |
Formulación de equinomicina, método de producción y método de uso de la misma
|
CN109414511B
(zh)
|
2016-04-18 |
2023-05-23 |
萨勒普塔医疗公司 |
用于治疗与酸性α-葡糖苷酶基因相关的疾病的反义寡聚物及其使用方法
|
WO2018157154A2
(en)
|
2017-02-27 |
2018-08-30 |
Translate Bio, Inc. |
Novel codon-optimized cftr mrna
|
WO2018163131A1
(en)
|
2017-03-10 |
2018-09-13 |
Quiapeg Pharmaceuticals Ab |
Releasable conjugates
|
WO2018209288A1
(en)
|
2017-05-12 |
2018-11-15 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded rna complexes and uses related thereto
|
AU2018268859A1
(en)
|
2017-05-16 |
2019-12-12 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding CFTR
|
US10590416B2
(en)
|
2017-07-06 |
2020-03-17 |
Arrowhead Pharmaceuticals, Inc. |
RNAi agents for inhibiting expression of alpha-ENaC and methods of use
|
CA3071755A1
(en)
|
2017-08-03 |
2019-02-07 |
Otsuka Pharmaceutical Co., Ltd. |
Drug compound and purification methods thereof
|
JP7394753B2
(ja)
|
2017-10-18 |
2023-12-08 |
サレプタ セラピューティクス, インコーポレイテッド |
アンチセンスオリゴマー化合物
|
US10722465B1
(en)
|
2017-12-08 |
2020-07-28 |
Quicksilber Scientific, Inc. |
Transparent colloidal vitamin supplement
|
CN111670072B
(zh)
|
2018-01-30 |
2023-10-27 |
生命技术公司 |
用于智能分子分析系统的工作流中的仪器、装置和消耗品
|
CN111629759A
(zh)
|
2018-03-09 |
2020-09-04 |
奎亚培格制药公司 |
可释放的抗体结合物
|
JP2021518401A
(ja)
|
2018-03-21 |
2021-08-02 |
コロラド ステート ユニバーシティー リサーチ ファウンデーション |
がんワクチン組成物及びその使用方法
|
EP3773505A4
(de)
|
2018-03-30 |
2021-12-22 |
Insmed Incorporated |
Verfahren zur kontinuierlichen herstellung von liposomalen arzneimittelprodukten
|
WO2019195738A1
(en)
|
2018-04-06 |
2019-10-10 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
US20210348162A1
(en)
|
2018-08-16 |
2021-11-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
EP3841208A1
(de)
|
2018-08-24 |
2021-06-30 |
Translate Bio, Inc. |
Verfahren zur reinigung von messenger-rna
|
EP3849660A1
(de)
|
2018-09-12 |
2021-07-21 |
QuiaPEG Pharmaceuticals AB |
Lösbare glp-1-konjugate
|
EP3887516A1
(de)
|
2018-11-29 |
2021-10-06 |
Flagship Pioneering Innovations V, Inc. |
Verfahren zur modulation von rna
|
CA3126087A1
(en)
|
2019-02-25 |
2020-09-03 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
US11291702B1
(en)
|
2019-04-15 |
2022-04-05 |
Quicksilver Scientific, Inc. |
Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
|
BR112022003860A2
(pt)
|
2019-09-03 |
2022-08-16 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para inibir a expressão do gene lect2
|
US20220389429A1
(en)
|
2019-10-04 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
EP4051796A1
(de)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
|
BR112022015770A2
(pt)
|
2020-02-10 |
2022-10-11 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para silenciar a expressão de vegf-a
|
EP4114456A1
(de)
|
2020-03-06 |
2023-01-11 |
The Colorado State University Research Foundation |
Herstellung von impfstoffen mit inaktivierten sars-cov-2-viruspartikeln
|
EP4127171A2
(de)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
|
TW202204618A
(zh)
|
2020-04-06 |
2022-02-01 |
美商艾爾妮蘭製藥公司 |
用於靜默myoc表現之組合物及方法
|
CA3179678A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
EP4153746A1
(de)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
|
TW202227124A
(zh)
|
2020-08-21 |
2022-07-16 |
瑞士商諾華公司 |
用於體內產生car表現細胞的組成物和方法
|
EP4326873A1
(de)
|
2021-04-22 |
2024-02-28 |
Dana-Farber Cancer Institute, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
WO2024026452A1
(en)
|
2022-07-29 |
2024-02-01 |
Repertoire Immune Medicines, Inc. |
T cell epitopes associated with type 1 diabetes
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|